Repaglinide and Olmetec drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Repaglinide (repaglinide) and Olmetec (olmesartan medoxomil). Common drug interactions include confusional state among females and pancreatitis acute among males.

The phase IV clinical study analyzes what interactions people have when they take Repaglinide and Olmetec. It is created by eHealthMe based on reports of 21 people who take the same drugs from the FDA, and is updated regularly.

What is Repaglinide?

Repaglinide has active ingredients of repaglinide. It is often used in diabetes. eHealthMe is studying from 8,226 Repaglinide users. Check the latest studies of Repaglinide.

What is Olmetec?

Olmetec has active ingredients of olmesartan medoxomil. It is often used in high blood pressure. eHealthMe is studying from 7,904 Olmetec users. Check the latest studies of Olmetec.

On Jul, 14, 2026

21 people who take Repaglinide and Olmetec together, and have interactions are studied.

Repaglinide and Olmetec drug interactions.

What are the common drug interactions of Repaglinide and Olmetec, by gender? *:

female:

Confusional state
Hyponatraemia (abnormally low level of sodium in the blood; associated with dehydration)
International normalised ratio increased
Lethargy (tiredness)
Oral mucosa erosion (erosion of mouth mucous membrane)
Palmar-plantar erythrodysaesthesia syndrome (hand-foot syndrome)
Cardiac failure chronic
Disorientation (disability in which the senses of time, direction, and recognition of people and places)
Somnolence (a state of near-sleep, a strong desire for sleep)
Sopor (sleep)

male:

Pancreatitis acute (sudden inflammation of pancreas)
Dyspnoea (difficult or laboured respiration)
Hypokinesia (decreased bodily movement)
Hypoxic-ischaemic encephalopathy (a condition that occurs when the entire brain is deprived of an adequate oxygen supply, but the deprivation isn't total)
Loss of consciousness
Pulmonary congestion (congestion in the lungs)
Respiratory arrest (cessation of normal respiration due to failure of the lungs to function effectively)
Stress cardiomyopathy (stress-induced chronic disease of the heart muscle)
Ventricular hypokinesia (muscle of one's heart does not contract as much as most peoples' hearts do)
Alanine aminotransferase increased

What are the common drug interactions of Repaglinide and Olmetec, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

Oral mucosa erosion (erosion of mouth mucous membrane)
Palmar-plantar erythrodysaesthesia syndrome (hand-foot syndrome)
Back pain
Pancreatitis acute (sudden inflammation of pancreas)
Prostatomegaly (enlargement of the prostate)

50-59:

Cholelithiasis (the presence or formation of gallstones in the gallbladder or bile ducts)
Pancreatitis acute (sudden inflammation of pancreas)
Acute coronary syndrome (acute chest pain and other symptoms that happen because the heart does not get blood)
Akinesia (loss of control of voluntary muscle movements)
Arrhythmia (irregular heartbeat)
Cardio-respiratory arrest (sudden dysfunction of heart and lungs)
Cerebral disorder (brain disease)
Dyspnoea (difficult or laboured respiration)
Heart rate increased
Hyperkinetic heart syndrome (hyperkinetic heart disease is when the heart is beating faster that it should be)

60+:

Alanine aminotransferase increased
Aspartate aminotransferase increased
Myocarditis (inflammation of heart muscle myocardium)
Pneumonia
Prothrombin time ratio decreased
Anuria (failure of the kidneys to produce urine)
Cardiac failure chronic
Disorientation (disability in which the senses of time, direction, and recognition of people and places)
Dyspnoea (difficult or laboured respiration)
Gastrointestinal haemorrhage (bleeding gastrointestinal tract)

What are the existing conditions these people have? *

Type 2 Diabetes: 10 people, 47.62%
Pain: 4 people, 19.05%
Gouty Arthritis (joint inflammation with crystal formation): 4 people, 19.05%
Atrial Fibrillation/flutter (atrial fibrillation and flutter are abnormal heart rhythms in which the atria, or upper chambers of the heart, are out of sync with the ventricles): 4 people, 19.05%
Cardiac Failure Congestive: 3 people, 14.29%
Metastatic Renal Cell Carcinoma (spreadable kidney cell tumour): 2 people, 9.52%

* Approximation only. Some reports may have incomplete information.

Do you take Repaglinide and Olmetec?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously